Scilex Holding Company Announces Settlement Agreement With Takeda Pharmaceuticals To Resolve Paragraph IV Patent Infringement Lawsuit Relating To Scilex's Filing Of A sNDA With FDA Seeking To Expand Label For Gloperba
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company has reached a settlement agreement with Takeda Pharmaceuticals to resolve a Paragraph IV patent infringement lawsuit. This lawsuit was related to Scilex's filing of a supplemental New Drug Application (sNDA) with the FDA, aiming to expand the label for Gloperba.
March 20, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex's settlement with Takeda Pharmaceuticals resolves a significant legal hurdle, potentially accelerating Gloperba's label expansion and positively impacting Scilex's market position.
The settlement of the patent infringement lawsuit removes a major obstacle for Scilex, allowing the company to proceed with its plans to expand Gloperba's label. This resolution is likely to be viewed positively by investors, as it clears legal uncertainties and paves the way for potential revenue growth from Gloperba.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90